Synvista Therapeutics, Inc. - Additional Proxy Soliciting Materials (definitive) (DEFA14A)
04 Junho 2008 - 1:28PM
Edgar (US Regulatory)
SCHEDULE
14A
PROXY
STATEMENT PURSUANT TO SECTION 14(a) OF
THE
SECURITIES
EXCHANGE ACT OF 1934
Filed
by
the Registrant
x
Filed
by a Party other than the Registrant
o
Check
the
appropriate box:
o
|
|
Preliminary
Proxy Statement
|
|
|
Confidential,
for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
|
|
|
Definitive
Proxy Statement
|
x
|
|
Definitive
Additional Materials
|
|
|
Soliciting
Material Pursuant to §240.14a-12
|
SYNVISTA
THERAPEUTICS, INC.
(Name
of
Registrant as Specified in its Charter)
N/A
(Name
of
Person(s) Filing Proxy Statement, if other than the Registrant)
Payment
of Filing Fee (Check the appropriate box):
|
|
No
fee required.
|
|
|
|
|
|
Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and
0-11.
|
|
(1)
Title of each class of securities to which transaction
applies:
|
|
|
|
(2)
Aggregate number of securities to which transaction
applies:
|
|
|
|
(3)
Per unit price or other underlying value of transaction computed
pursuant
to Exchange Act Rule 0-11 (set forth the amount on which the filing
fee is
calculated and state how it was determined):
|
|
|
|
(4)
Proposed maximum aggregate value of transaction:
|
|
|
|
(5)
Total fee paid:
|
o
Fee
paid previously with preliminary materials.
|
|
o
Check
box if any part of the fee is offset as provided by Exchange
Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee
was paid
previously. Identify the previous filing by registration statement
number,
or the Form or Schedule and the date of its
filing.
|
|
(1)
|
Amount
previously paid:
|
|
|
|
(2)
|
Form,
Schedule or Registration Statement No.:
|
|
|
|
(3)
Filing
Party:
|
|
|
|
(4)
Date
Filed:
|
|
|
|
|
|
|
|
|
|
|
|
|
S.Y. Bancorp (AMEX:SYI)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
S.Y. Bancorp (AMEX:SYI)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
Notícias em tempo-real sobre Synvista Therapeutics, da American Stock Exchange bolsa de valores: 0 artigos recentes
Mais Notícias de Synvista Therapeutics, Inc.